K. Goldenthal

发表

Control of Viral Infections and Diseases

K. Zoon, K. Goldenthal, K. Midthun, 1996 .

Combined Vaccines and Simultaneous Administration: Current Issues and Perspectives. Conference proceedings. Bethesda, Maryland, July 28-30, 1993.

B. P. Lewis, D. Burns, K. Goldenthal, 1995, Annals of the New York Academy of Sciences.

Kawasaki disease and immunisation: Standardised case definition & guidelines for data collection, analysis.

J. Newburger, N. Dahdah, S. D. de Ferranti, 2016, Vaccine.

Pre-lysosomal divergence of alpha 2-macroglobulin and transferrin: a kinetic study using a monoclonal antibody against a lysosomal membrane glycoprotein (LAMP-1).

I. Pastan, M. Willingham, J. August, 1988, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

Prelicensure evaluation of combination vaccines.

L. Ball, K. Goldenthal, L. A. Falk, 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Testing and Licensure of Combination Vaccines for the Prevention of Infectious Diseases

K. Goldenthal, K. Midthun, L. A. Falk, 1999 .

Kawasaki disease and immunisation: A systematic review.

J. Newburger, N. Dahdah, S. D. de Ferranti, 2017, Vaccine.

Comparison of the intracellular pathways of transferrin recycling and vesicular stomatitis virus membrane glycoprotein exocytosis by ultrastructural double-label cytochemistry.

I. Pastan, M. Willingham, K. Hedman, 1987, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

Public health implications of emerging vaccine technologies.

D. Lawrence, J. L. La Montagne, J. Boslego, 1995, Pharmaceutical biotechnology.

Initial steps in receptor-mediated endocytosis. The influence of temperature on the shape and distribution of plasma membrane clathrin-coated pits in cultured mammalian cells.

I. Pastan, M. Willingham, K. Goldenthal, 1984, Experimental cell research.

Evaluation of safety and immunogenicity of recombinant influenza hemagglutinin (H5/Indonesia/05/2005) formulated with and without a stable oil-in-water emulsion containing glucopyranosyl-lipid A (SE+GLA) adjuvant.

S. Reed, J. Treanor, P. Patriarca, 2013, Vaccine.

Overview—Combination Vaccines and Simultaneous Administration: Past, Present, and Future

B. P. Lewis, J. Williams, D. Burns, 1995, Annals of the New York Academy of Sciences.

Normal sister chromatid exchange frequencies during growth of a transplantable murine myeloid leukemia.

W. Au, K. Goldenthal, 1985, Cancer genetics and cytogenetics.

Serial section analysis of clathrin-coated pits in rat liver sinusoidal endothelial cells.

I. Pastan, M. Willingham, K. Goldenthal, 1985, Experimental cell research.

Preventive Human Papillomavirus (HPV) Vaccines - Background Information Vaccines and Related Biological Products Advisory Committee

Robert W. Anderson, T. Finn, J. Weir, 2001 .

Developing new smallpox vaccines.

M. Merchlinsky, C. Kleppinger, S. Rosenthal, 2001, Emerging infectious diseases.

Workshop Report: Traditional Approach Preventive HIV Vaccines: What Are the Cell Substrate and Inactivation Issues?1

K. Goldenthal, R. Sheets, 1998 .

Efficacy of Recombinant Influenza Vaccine in Adults 50 Years of Age or Older

M. Cox, P. Patriarca, K. Goldenthal, 2017, The New England journal of medicine.

Recombinant bacillus Calmette-Guérin as a potential vector for preventive HIV type 1 vaccines.

S. Osmanov, G. Ferrari, J. Esparza, 2000, AIDS research and human retroviruses.

Preventive HIV-1 Vaccines

T. Cvetkovich, D. Chandler, K. Goldenthal, 2004 .

Postfixation detergent treatment for immunofluorescence suppresses localization of some integral membrane proteins.

M. Willingham, J. August, K. Hedman, 1985, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

Evaluation of the safety, reactogenicity and immunogenicity of FluBlok® trivalent recombinant baculovirus-expressed hemagglutinin influenza vaccine administered intramuscularly to healthy adults 50-64 years of age.

M. Cox, R. Baxter, P. Patriarca, 2011, Vaccine.

Safety and Immunogenicity of a Recombinant Influenza Vaccine: A Randomized Trial

J. Treanor, M. Cox, P. Patriarca, 2018, Pediatrics.

Selected regulatory and scientific topics for candidate rotavirus vaccine development.

K. Goldenthal, K. Midthun, L. S. Henchal, 1996, The Journal of infectious diseases.

Intent-to-treat analysis and preventive vaccine efficacy.

P A Lachenbruch, P. Lachenbruch, A. Horne, 2000, Vaccine.

Sister-chromatid exchanges in mouse embryos after exposure to ultrasound in utero.

W. Au, P. Corry, K. Goldenthal, 1982, Mutation research.

Clinical safety evaluation of combination vaccines.

A. Horne, K. Goldenthal, K. Midthun, 1998, Developments in biological standardization.

Randomized Comparison of Immunogenicity and Safety of Quadrivalent Recombinant Versus Inactivated Influenza Vaccine in Healthy Adults 18–49 Years of Age

M. Cox, P. Patriarca, K. Goldenthal, 2017, The Journal of infectious diseases.

Evaluating the safety of new vaccines: summary of a workshop.

Susan S Ellenberg, Mary A Foulkes, S. Ellenberg, 2005, American journal of public health.

Template protocol for clinical trials investigating vaccines--focus on safety elements.

Robert T. Chen, S. Kochhar, D. Nalin, 2013, Vaccine.

Stable emulsion (SE) alone is an effective adjuvant for a recombinant, baculovirus-expressed H5 influenza vaccine in healthy adults: A Phase 2 trial.

J. Treanor, P. Patriarca, K. Goldenthal, 2017, Vaccine.

Workshop on the control and standardization of nucleic acid vaccines. Bethesda, Maryland, 8 February 1996.

R. Rabinovich, F. Vogel, K. Goldenthal, 1997, Vaccine.